Downloadable_Slides
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Brexpiprazole: Clinical Trial<br />
• Rationale<br />
– D2 partial agonist: selective impact on<br />
dopamine system<br />
• Subjects: 636 subjects with<br />
schizophrenia<br />
• Design: 6-week, randomized, doubleblind,<br />
placebo-controlled trial<br />
• Treatment: 0.25 mg, 2 mg, 4 mg<br />
dosing<br />
• Outcomes:<br />
– Placebo vs 2 mg dose: total P=.0006,<br />
positive P=.003, and negative<br />
symptoms (P=.0007)<br />
– Placebo vs 4 mg dose total P
Change language